Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
arcticnovartis
Wed, 10/04/2023 – 07:04
Read more about Novartis executes Sandoz Spin-off, completing strategic transformatio…
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
arcticnovartis
Mon, 10/02/2023 – 07:19
Read more about Novartis…
Novartis completes divestment of ‘front of eye’ ophthalmology assets
arcticnovartis
Fri, 09/29/2023 – 16:04
Read more about Novartis completes divestment of ‘front of eye’ ophthalmology assets
Divestment includes Xiidra®, on-market tre…
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
arcticnovartis
Tue, 09/26/2023 – 07:19
Read more about Sandoz receives European Commission approval for Tyruko® (nata…
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
arcticnovartis
Mon, 09/25/2023 – 07:19
…
Novartis confirms Sandoz Spin-off for October 4, 2023
arcticnovartis
Mon, 09/25/2023 – 07:19
Read more about Novartis confirms Sandoz Spin-off for October 4, 2023
Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs …
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
arcticnovartis
Mon, 09/18/2023 – 07:19
Read more about Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
…
Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
arcticnovartis
Fri, 09/15/2023 – 11:49
Read more about Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
…